Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Durect Corp. (DRRX)
NASDAQ:DRRX
Holding DRRX?
Track your performance easily
DRRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.48 - $1.88
Previous Close$0.9
Volume178.28K
Average Volume (3M)85.69K
Market Cap
$27.93M
Enterprise Value$31.30M
Total Cash (Recent Filing)$10.38M
Total Debt (Recent Filing)$13.74M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 11, 2025EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding31,041,981
10 Day Avg. Volume164,913
30 Day Avg. Volume85,691
Standard Deviation0.29
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)21.11
Price to Sales (P/S)3.25
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.08
Enterprise Value/Gross Profit4.58
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$6.75Price Target Upside699.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Durect News
PremiumCompany Announcements
DURECT Corporation’s Q3 2024 Financial Highlights
PremiumCompany Announcements
Durect Corp Annual Meeting Decisions and Shareholder Votes
Bulls Say, Bears Say
Bulls Say
Clinical Study DesignThe FDA has agreed to a single pivotal study to enroll patients only from U.S. sites, which could enhance the trial's success by reducing variability.
Clinical Trial ResultsManagement believes larsucosterol has a high probability of success in meeting the 90-day survival primary endpoint based on data from the Phase 2b AHFIRM trial.
Regulatory ApprovalThe recent Breakthrough Therapy designation is viewed as strong validation of the drug's value in alcohol-associated hepatitis.
Bears Say
Financial PerformanceWith a current cash runway of about 4½ months, DURECT says 'everything is on the table' in terms of alternatives to raise capital.
Funding And InvestmentThere remains significant uncertainty regarding the available options to finance this study.
Risk AssessmentDURECT is viewed as a significant 'going concern' risk with its current cash runway 'through 2024'.
---
Ownership Overview
12.21% Insiders
4.55% Mutual Funds
14.22% Other Institutional Investors
65.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DRRX FAQ
What was Durect Corp.’s price range in the past 12 months?
Durect Corp. lowest stock price was $0.48 and its highest was $1.88 in the past 12 months.
What is Durect Corp.’s market cap?
Currently, no data Available
When is Durect Corp.’s upcoming earnings report date?
Durect Corp.’s upcoming earnings report date is Mar 11, 2025 which is in 82 days.
How were Durect Corp.’s earnings last quarter?
Durect Corp. released its earnings results on Nov 13, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.023.
Is Durect Corp. overvalued?
According to Wall Street analysts Durect Corp.’s price is currently Undervalued.
Does Durect Corp. pay dividends?
Durect Corp. does not currently pay dividends.
What is Durect Corp.’s EPS estimate?
Durect Corp.’s EPS estimate is -$0.02.
How many shares outstanding does Durect Corp. have?
Durect Corp. has 31,041,980 shares outstanding.
What happened to Durect Corp.’s price movement after its last earnings report?
Durect Corp. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went down -7.438%.
Which hedge fund is a major shareholder of Durect Corp.?
Among the largest hedge funds holding Durect Corp.’s share is Moore Capital Management LP. It holds Durect Corp.’s shares valued at N/A.
---
Durect Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.75 (699.29% Upside)
$6.75 (699.29% Upside)
Hedge Fund Trend
Decreased
By 75.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.37%
12-Months-Change
Fundamentals
Return on Equity
-218.51%
Trailing 12-Months
Asset Growth
-56.03%
Trailing 12-Months
Company Description
Durect Corp.
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
---
DRRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights several positive developments, particularly around the preparation and regulatory progress for the Phase III trial of larsucosterol. However, the termination of the POSIMIR licensing agreement and the urgent need for funding to proceed with critical trials present significant challenges. Overall, the sentiment is cautiously optimistic with a focus on future potential balanced by immediate financial needs.Read More>---
DRRX Stock 12 Month Forecast
Average Price Target
$6.75
▲(699.29% Upside)
Technical Analysis
Best Analysts Covering DRRX
1 Year
1 Year Success Rate
2/17 ratings generated profit
1 Year Average Return
-40.72%
reiterated a buy rating 23 days ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -40.72% per trade.
---